| Literature DB >> 23533815 |
Abubakr Ahmed1, Gaitri Sadadcharam, Felicity Huisma, Katrina Fogarty, Muhammad Mushtaque, Azher Shafiq, Paul Redmond.
Abstract
Background. Although postoperative complications are common after lymph node dissection, its association with disease recurrence has not yet been fully investigated. Methods. A retrospective review of a prospectively maintained database was conducted, looking at all malignant melanoma patients with sentinel nodes positive disease requiring axillary or inguinal dissection between 2002 and 2011. Results. A total of 124 patients required nodal clearance from 317 patients with stage I/II malignant melanoma who had undergone sentinel lymph node biopsy. Of these, 104 patients met the inclusion criteria and were divided into inguinal lymph node dissections (ILND; n = 63) or axillary lymph node dissections (ALND; n = 41). Immunohistochemical deposits had higher detection rate in ALND (P = 0.01). The ILND patients had a higher recurrence rate (84.1% versus 63.4%; P = 0.02) and mortality (68.3% versus 48.8%; P = 0.05) without a significant difference in complications. In patients whom complications developed, 75% of the ILND group and 71.4% of the ALND group had disease recurrence, but without reaching a statistical value as an independent predictor of melanoma recurrence. Conclusion. Complications are common following ILND and ALND; however there is no significant difference in complications rates between the groups with some associations with recurrence without reaching a significant difference.Entities:
Year: 2013 PMID: 23533815 PMCID: PMC3600306 DOI: 10.1155/2013/382138
Source DB: PubMed Journal: ISRN Surg ISSN: 2090-5785
Demographic and pathological characteristics.
| Characteristics | Total ( | Inguinal dissection ( | Axillary dissection ( |
|
|---|---|---|---|---|
| Gender | ||||
| Male | 55 (52.9%) | 29 (46%) | 26 (63.4%) | 0.083 |
| Female | 49 (47.1%) | 34 (54%) | 15 (36.5%) | |
| Age | ||||
| Mean ± SD | 54.5 (±16.98) | 57.4 (±16.70) | 50 (±16.06) |
|
| Median | 56 | 60 | 51 | |
| Primary site | ||||
| Extremity | 88 (84.6%) | 61 (96.8%) | 27 (65.9%) |
|
| Trunk | 16 (15.3%) | 2 (3.2%) | 14 (34.1%) |
|
| Breslow (mm) | ||||
| Mean ± SD | 4.55 (±4.01) | 5.03 (±4.49) | 3.8 (±3.06) | 0.11 |
| Median | 3.5 | 3.8 | 3 | |
| 1–1.79 mm | 17 (16.3%) | 10 (15.9%) | 7 (17.1%) | 0.872 |
| 1.80–3.5 mm | 36 (34.6%) | 19 (30.2%) | 17 (41.5%) | 0.236 |
| >3.5 mm | 51 (49%) | 34 (54%) | 17 (41.5%) | 0.213 |
| Clarke's level | ||||
| III or > | 26 (25%) | 16 (25.4%) | 10 (24.4%) | 0.908 |
| IV | 67 (64.4%) | 38 (60.3%) | 29 (70.7%) | 0.278 |
| V | 11 (10.6%) | 9 (14.3%) | 2 (4.9%) | 0.127 |
| Ulceration | ||||
| Present | 40 (38.5%) | 27 (42.9%) | 13 (31.7%) | 0.235 |
| Absent | 35 (51%) | 29 (46%) | 24 (58.5%) | 0.213 |
| Unknown | 11 (10.6%) | 7 (11.1%) | 4 (9.75%) | 0.826 |
| Lymph vascular invasion | ||||
| Present | 18 (17%) | 12 (19%) | 6 (14.6%) | 0.561 |
| Absent | 72 (69.2%) | 43 (68.3%) | 29 (70.7%) | 0.789 |
| Unknown | 14 (13.5%) | 8 (12.7%) | 6 (14.6%) | 0.777 |
| Melanoma type | ||||
| Superficial spreading | 51 (49%) | 29 (46%) | 22 (53.7%) | 0.447 |
| Nodular | 29 (27.9%) | 16(25.4%) | 13 (31.7%) | 0.483 |
| Lentigo maligna | 7 (6.7%) | 4 (6.3%) | 3 (7.3%) | 0.847 |
| Acral lentiginous | 13 (12.5%) | 11 (17.5%) | 2 (4.9%) |
|
| Amelanotic | 4 (3.8%) | 3 (4.8%) | 1 (2.4%) | 0.547 |
Nodal characteristics, recurrence and survival.
| Characteristics | Inguinal dissection ( | Axillary dissection ( |
|
|---|---|---|---|
| Sentinel node | |||
| Macrometastasis | 18 (28.6%) | 13 (31.7%) | 0.772 |
| Micrometastasis | 44 (69.8%) | 22 (53.7%) | 0.106 |
| Immunohistochemical | 1 (1.6%) | 6 (14.4%) |
|
| Total nodes (mean ± SD) | 11.45 (±4.9) | 19.76 (±10.8) |
|
| Median of total nodes | 11 | 18 | — |
| Positive nodes (mean ± SD) | 1.93 (±3.25) | 2.12 (±3.27) | 0.722 |
| Median of positive nodes | 1 | 1 | — |
| % of positive nodes (mean ± SD) | 16.84 (±24.56) | 14.37 (±24.87) | 0.615 |
| Recurrence rate | 53 (84.1%) | 26 (63.4%) |
|
| Mean time to recurrence (months) | 28.9 (±24) | 34 (±27.7) | 0.206 |
| Site of recurrence | |||
| Local or in transit | 13 (20.6%) | 6 (14.6%) | 0.887 |
| Nodal | 16 (25.4%) | 7 (17.5%) | 0.764 |
| Distant | 42 (66.7%) | 22 (53.7%) | 0.567 |
| Mortality | 43 (68.3%) | 20 (48.8%) |
|
Complications rate.
| Complications | GLND | ALND |
|
|---|---|---|---|
| Overall | 25 (39.7%) | 14 (34.1%) | 0.569 |
| Lymphedema | 14 (22.2%) | 6 (14.6%) | 0.337 |
| Wound infection | 6 (9.5%) | 6 (14.6%) | 0.425 |
| Seroma | 13 (20.6%) | 6 (14.6%) | 0.439 |
| Haematoma | 2 (3.2%) | 1 (2.4%) | 0.827 |
| Chronic pain | 2(3.2%) | 0 | 0.249 |
Analysis of risk factors associated with complications.
| Risk factors for complications | ILND |
| ALND |
| ILND versus ALNC |
|---|---|---|---|---|---|
| Age > 60 | 16/32 (50%) | 0.089 | 6/14 (42.9%) | 0.397 | 0.655 |
| Male | 11 (37.9%) | 0.793 | 12 (46.2%) |
| 0.357 |
| Female | 14 (41.2%) | — | 2 (13.3%) | — | 0.055 |
| Extremity | 24 (39.3%) | 0.762 | 8 (29.6%) | 0.397 | 0.382 |
| Trunk | 1 (50%) | — | 6 (42.8%) | — | 0.849 |
| LVI | 7 (58.3%) | 0.935 | 3 (50%) | 0.954 | 0.778 |
| Ulceration | 13 (48.1%) | 0.324 | 5 (38.5%) | 0.228 | 0.131 |
| Breslow > 3.5 | 12 (35.3%) | 0.441 | 5 (29.4%) | 0.591 | 0.674 |
| Clark > 4 | 20 (42.6%) |
| 10 (32.2%) | 0.653 | 0.201 |
| Positive nodes > 30% | 4/12 (25%) | 0.935 | 3/7 (42.8%) | 0.558 | 0.783 |
| Melanoma type | |||||
| Superficial spreading | 11 (37.9%) | 0.793 | 8 (36.4%) | 0.747 | 0.909 |
| Nodular | 7 (43.8%) | 0.700 | 4 (30.8%) | 0.756 | 0.474 |
| Lentigo maligna | 1 (25%) | 0.535 | 2 (66.7%) | 0.217 | 0.270 |
| Acral lentiginous | 4 (36.4%) | 0.804 | 0 | 0.296 | 0.305 |
| Amelanotic | 2 (66.7%) | 0.328 | 0 | 0.466 | 0.248 |
The association between complications and recurrence.
| Recurrence risk | ILND (63) |
| ALND (41) |
|
|---|---|---|---|---|
| Overall recurrence | 53 (84.1%) |
| 26 (63.4%) | — |
| Overall complications | 25 (39.7%) | 0.569 | 14 (34.1%) | — |
| Complication with recurrence | 19 (30.1%) | 0.152 | 10 (24.3%) | 0.433 |
| Lymphedema | 11 (17.4%) | 0.519 | 5 (12.2%) | 0.273 |
| Wound infection | 5 (7.9%) | 0.995 | 4 (9.7%) | 0.858 |
| Seroma | 11 (17.4%) | 0.957 | 4 (9.7%) | 0.858 |
| Haematoma | 2 (3.2%) | 0.532 | 19 (2.4%) | 0.442 |
| Chronic pain | 1 (1.6%) | 0.180 | 0 | 0.442 |